Statistics on Biotechnology Use Results by fields of operation Total Sectors. Biotechnology indicators by execution sector. Unidades: Total 2021 Companies P.A. Higher Education PNPI Companies that perform R+D in Biotechnology 1.498 1.299 120 66 13 %Companies according to biotechnology used: Genetic code 38 30,8 87,5 89,4 46,2 %Companies according to biotechnology used: Functional Companies 45 38,4 88,3 93,9 53,8 %Companies according to biotechnology used: Cellular and tissue culturing and engineering 28,9 21,5 73,3 86,4 61,5 %Companies according to biotechnology used: Bioprocesses 53,4 50,8 58,3 93,9 69,2 %Companies according to biotechnology used: Sub-cellular organisms 15,2 8,5 53,3 74,2 38,5 %Companies according to biotechnology used: Bio-computing 30,8 24 73,3 87,9 30,8 %Companies according to biotechnology used: Nanobiotechnology 18,2 12,1 54,2 72,7 15,4 %Companies according to biotechnology used: Other 15,3 16,9 3,3 7,6 0 Companies in which biotechnology activities are: Main and/or exclusive 603 559 31 3 10 Companies in which biotechnology activities are: A secondary line of business 318 230 41 46 1 Companies in which biotechnology activities are: A tool necessary for production 577 510 48 17 2 %Companies by field(s) of ultimate application of biotechnology use: Human health 50,4 45,5 76,7 95,5 69,2 %Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture 18,1 15,5 17,5 69,7 23,1 %Companies by field(s) of ultimate application of biotechnology use: Food products 33,6 32,3 24,2 81,8 7,7 %Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production 25,8 23,8 22,5 72,7 23,1 %Companies by field(s) of ultimate application of biotechnology use: Environment 19,1 15,6 25,8 78,8 7,7 %Companies by field(s) of ultimate application of biotechnology use: Industry 16,1 13,7 14,2 68,2 7,7 Personnel in R&D in biotechnology (no. of persons) 47.150 15.750 15.418 15.757 225 Personnel in R&D in biotechnology (no. of persons): Research personnel 30.817 8.379 9.510 12.778 150 Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel 16.333 7.371 5.908 2.979 75 Personnel in R&D in biotechnology (no. of persons). Women 26.632 8.711 9.684 8.101 136 Personnel in R&D in biotechnology (no. of persons). Women. Research personnel 16.540 4.510 5.637 6.314 79 Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel 10.091 4.200 4.047 1.787 57 Personnel in R&D in biotechnology (FTE) 32.901,7 11.528,6 11.271,7 9.934,5 166,9 Personnel in R&D in biotechnology (FTE): Research personnel 20.945,8 6.342,7 6.454,3 8.036 112,8 Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel 11.955,9 5.185,9 4.817,4 1.898,5 54,1 Personnel in R&D in biotechnology (FTE). Women 18.952,5 6.539,7 7.077,3 5.228 107,5 Personnel in R&D in biotechnology (FTE). Women: Research personnel 11.337,3 3.455,7 3.786,8 4.032,9 61,9 Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel 7.615,2 3.084 3.290,5 1.195,1 45,6 Internal expenditure on R&D (thousands of euros) 2.269.946 1.038.582 716.877 500.703 13.783 1) By nature of the expense: Current expenses 2.087.088 940.091 672.607 461.216 13.174 1.1) Remuneration to research personnel 872.195 321.570 252.863 293.131 4.630 1.2) Remuneration to technicians and auxiliary personnel 384.422 194.836 128.640 59.408 1.538 1.3) Other current expenses 830.471 423.685 291.103 108.677 7.006 2) By nature of the expense: Capital expenses 182.858 98.492 44.270 39.487 610 2.1) Land and buildings 20.307 10.199 2.712 7.373 23 2.2) Equipment and instruments 144.143 72.584 40.235 30.775 549 2.3) Acquisition of specific R+D software 8.159 5.721 1.102 1.303 33 2.4) Otros productos de propiedad intelectual específicos para I+D 10.250 9.987 222 36 5 1.1) By origin of the funds: Own funds 891.566 711.488 88.338 88.167 3.574 1.2) By origin of the funds: From companies 248.128 121.738 97.993 25.096 3.301 1.3) By origin of the funds: Public Administration funds 882.585 107.477 430.689 342.018 2.402 1.4) By origin of the funds: From Universities 3.851 192 1.388 2.220 50 1.5) By origin of the funds: From non profit private institutions 47.810 10.756 26.599 7.719 2.737 1.6) By origin of the funds: Foreign funds 196.006 86.931 71.871 35.483 1.720 Purchase of services R & D in Biotechnology to (thousands of euros) 174.934 145.557 23.461 3.058 2.858 Purchase of services R & D in Biotechnology to (thousands of euros): in Spain 123.461 95.915 21.807 3.035 2.704 Purchase of services R & D in Biotechnology to (thousands of euros): Abroad 51.472 49.642 1.654 23 154 %Companies that consider the following obstacles as very important considering biotechnology development: Access to capital 43 40,2 63,3 57,6 61,5 %Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information 12,5 13,2 6,7 9,1 15,4 %Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources 22,1 19 45 40,9 23,1 %Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain 13,6 11,5 26,7 33,3 7,7 %Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets 18,2 15,9 30 42,4 15,4 %Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels 18,9 17 27,5 39,4 30,8 %Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception 15,9 16,4 10 12,1 30,8 %Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements 40,5 40,5 40 37,9 61,5 %Companies that consider the following obstacles as very important considering biotechnology development: Time / cost 55,4 55 58,3 57,6 61,5 %Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting 21,9 21,9 24,2 18,2 23,1 Notas: '..'=data not available '.'=numeric piece of data equal to zero not resulting from rounding FTE: Full Time Equivalent (*) Total calculated from the total number of companies with related activities with Biotechnology and the total Companies from other sectors with activities in R&D in Biotechnology Fuente: National Statistics Institute